在阿尔茨海默病中分类前素
Michael S Wolfe1, Bruce A Yankner2
1Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Cell
|July 2, 2016
概括
亲属性阿尔茨海默氏病突变会改变蛋白酶的活性. 这项研究揭示了变化的细胞下定位是粉样β生成的关键,进步阿尔茨海默病的细胞生物学理解.
科学领域:
- 神经科学
- 分子生物学
- 遗传学
背景情况:
- 家族性阿尔茨海默病 (AD) 与前列林蛋白的突变有关.
- 这些突变增加了容易聚合的粉样β (Aβ) 的产生.
- 素突变影响Aβ生成的确切机制尚不清楚.
研究的目的:
- 阐明在家族性阿尔茨海默氏症中,前林突变导致β粉样蛋白 (Aβ) 产生增加的机制.
- 调查细胞下定位在突变的前列林蛋白酶活性中所起的作用.
主要方法:
- 使用基于细胞的测试来检查普雷西林的局部化和活性.
- 研究突变对细胞内的表素运输和功能的影响.
- 在不同的局部化条件下生成量化的粉样β (Aβ) .
主要成果:
- 素突变显著改变了这些蛋白酶的亚细胞局部.
- 局部化的变化直接与容易聚合的粉样β (Aβ) 异型的产生增加相关.
- 亚细胞贩运是前林介导的Aβ生产的关键调节步骤.
结论:
- 在家族性阿尔茨海默氏症中,细胞下定位的调节是前素突变驱动β粉样蛋白 (Aβ) 病理的核心机制.
- 这一发现为阿尔茨海默病的细胞生物学和潜在的治疗点提供了关键的见解.
更多相关视频
11:57Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
Published on: June 24, 2025
675
14:57Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
Published on: March 23, 2011
95.4K
相关概念视频
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Amyloid Fibrils
12.8K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.8K
Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
